C4 Therapeutics (CCCC) Return on Sales: 2020-2025
Historic Return on Sales for C4 Therapeutics (CCCC) over the last 6 years, with Sep 2025 value amounting to -3.96%.
- C4 Therapeutics' Return on Sales fell 82.00% to -3.96% in Q3 2025 from the same period last year, while for Sep 2025 it was -3.96%, marking a year-over-year decrease of 82.00%. This contributed to the annual value of -2.96% for FY2024, which is 342.00% up from last year.
- Per C4 Therapeutics' latest filing, its Return on Sales stood at -3.96% for Q3 2025, which was down 21.37% from -3.26% recorded in Q2 2025.
- Over the past 5 years, C4 Therapeutics' Return on Sales peaked at -1.83% during Q4 2021, and registered a low of -8.11% during Q2 2023.
- Moreover, its 3-year median value for Return on Sales was -3.96% (2025), whereas its average is -4.63%.
- In the last 5 years, C4 Therapeutics' Return on Sales crashed by 614bps in 2023 and then spiked by 444bps in 2024.
- Over the past 5 years, C4 Therapeutics' Return on Sales (Quarterly) stood at -1.83% in 2021, then plummeted by 196bps to -3.79% in 2022, then slumped by 259bps to -6.38% in 2023, then skyrocketed by 342bps to -2.96% in 2024, then tumbled by 82bps to -3.96% in 2025.
- Its Return on Sales stands at -3.96% for Q3 2025, versus -3.26% for Q2 2025 and -2.60% for Q1 2025.